Copper radionuclides are rapidly emerging as potential diagnostic and therapeutic tools in oncology, particularly ⁶⁴Cu-radiopharmaceuticals for targeting neuroendocrine, prostate, and hypoxic tumors. Unexpectedly, experimental results are also revealing the impressive biological behavior of simple [⁶⁴Cu²⁺] ions. For example, it has been demonstrated that administration of ionic [⁶⁴Cu²⁺] in physiological solution allows the selective targeting of a variety of malignancies. These remarkable biological properties appear to be crucially linked to the natural role of copper ions in cell proliferation. Here, we review the current status of ⁶⁴Cu-radiopharmaceuticals in molecular imaging and cancer therapy.

铜放射性核素正迅速成为肿瘤学中潜在的诊断和治疗工具，尤其是针对神经内分泌，前列腺和低氧肿瘤的^64种铜放射性药物。出乎意料的是，实验结果还揭示了简单的[ ⁶⁴ Cu ²⁺ ]离子令人印象深刻的生物学行为。例如，已证明在生理溶液中施用离子[ ⁶⁴ Cu ²⁺ ]可以选择性靶向多种恶性肿瘤。这些非凡的生物学特性似乎与铜离子在细胞增殖中的天然作用至关重要。在这里，我们回顾一下⁶⁴的当前状态分子成像和癌症治疗中的铜放射性药物。